Usando inhibidores de PARP en el tratamiento de las pacientes con cáncer de ovario: Cómo, Cuando, A quién y Por qué

Study 10 and ARIEL2:

Integrated Efficacy and Safety Populations

Study 10

ARIEL2

Safety Population (n=377)

Criteria

•

Diagnosis of high-grade serous or endometrioid epithelial ovarian, fallopian tube

or primary peritoneal carcinoma (HGOC)

•

Received ≥1 dose of rucaparib 600 mg

n=62

n=315

Efficacy population (n=106)

Criteria

•

Received ≥2 prior chemotherapies, including

≥2 platinum-based regimens

•

Had a

deleterious germline

BRCA

1/2 or somatic

BRCA

1/2 mutation

•

Received ≥1 dose of rucaparib 600 mg

n=42

n=64

Oza AM et al.

Gynecol Oncol

. 2017;147:267–275